速递｜全球卖255亿美元的司美格鲁肽，中国国产+1！正大天晴司美格鲁肽申报上市

Core Viewpoint - The article discusses the rapid development and market entry of Semaglutide, a GLP-1 receptor agonist, by Zhengda Tianqing's subsidiary, Lianyungang Runzhong Pharmaceutical, highlighting its potential impact on the obesity and diabetes treatment market in China [4][8]. Group 1: Product Development - Zhengda Tianqing's Semaglutide injection has submitted its market application on December 11, 2025, entering the final stage of the approval process [4]. - The product was first clinically submitted in June 2023, received approval for trials in August, and began testing in October, indicating a faster-than-average development pace in the industry [4]. - Two pivotal Phase III clinical trials are underway: one for type 2 diabetes treatment, which started in January 2024 and completed in June 2024, and another for obesity management, which began in December 2024 and completed patient recruitment in August 2024 [4]. Group 2: Market Context - Semaglutide is classified as a GLP-1 receptor agonist, initially used for improving blood sugar levels in type 2 diabetes but has expanded to obesity management due to its significant weight loss effects [5]. - The drug mimics natural GLP-1 in the body, delaying gastric emptying, enhancing satiety, and reducing food intake while promoting insulin secretion and suppressing glucagon in response to elevated blood sugar levels [5][16]. - In the first three quarters of this year, the original Semaglutide developed by Novo Nordisk achieved approximately $25.5 billion in global sales, making it one of the most successful GLP-1 drugs [8]. Group 3: Competitive Landscape - The entry of Zhengda Tianqing's domestically produced Semaglutide into the market is expected to accelerate competition in China's GLP-1 market, which is poised to welcome more domestic players [8].